DOI: https://doi.org/10.22141/2224-1507.9.4.2019.191923

Controversies related to determination of the glucocorticoid-induced osteoporosis intervention threshold: who are the patients?

I.Yu. Golovach

Abstract


Glucocorticoid-induced osteoporosis is the most common cause of secondary osteoporosis. The research demonstrates that oral administration of glucocorticoids often result in rapid bone loss and an increased risk of fractures during several months. The urgency of glucocorticoid-induced osteoporosis as a public health problem is caused by the frequent use of glucocorticoids by patients with various chronic diseases resulting in high level of osteoporosis. The glucocorticoid-induced osteoporosis develops due to the inhibition of bone formation, accompanied by an early but short-term bone resorption increase. An increase in the RANKL/OPG ratio, sclerostin expression growth, activation of PPARgR2, as well as hypogonadism, impaired absorption of calcium in the intestine, and a decrease of the insulin-like growth factor 1 production are among many mechanisms underlying the bone metabolism disorders caused by the long-term use of glucocorticoids. Despite available and effective preventive measures, the bone condition and risk of fractures for many patients who start or conti­nue glucocorticoid therapy are not adequately assessed. The thre­shold values of daily doses of glucocorticoids (≥ 2.5 mg/day) and the duration of their administration (≥ 3 months) at which patients’ risk of fractures and the necessity of treatment with antiosteoporotic drugs should be assessed were identified. National guidelines for the management of glucocorticoid-induced osteoporosis offer different approaches to determination of the interventions thre­shold based on the use of various criteria. The 10-year probability of fractures based on the clinical risk factors, with or without bone mine­ral density assessment, is calculated and adjusted for regional fracture rate and mortality with the Fracture Risk Assessment Tool (FRAX). Despite limitations, this algorithm is the most effective in defining the interventions thresholds. The 2017 American College of Rheumatology guidelines indicate that the initial absolute risk of fractures should be assessed using the FRAX and taking into account the doses of glucocorticoids and bone mineral density test results no later than 6 months from the start of glucocorticoids therapy.


Keywords


glucocorticoid-induced osteoporosis; glucocorticoids; daily dose; pathogenesis; intervention thre­shold; fracture risk; FRAX; treatment; review

Full Text:

PDF

References


Golovach IYu. Gljukokortykoi'd-indukovanyj osteoporoz [Glucocorticoid-induced osteoporosis]. Kyiv: Medkniga; 2019. 240 p. (in Ukrainian).

Bultink IE, Baden M, Lems WF. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2013;14(2):185-197. https://doi.org/10.1517/14656566.2013.761975.

McKay LI, Cidlowski JA. Cross-talk between nuclear factor-kappa B and the steroid hormone receptors: mechanisms of mutual antagonism. Mol Endocrinol. 1998;12(1):45-56. https://doi.org/10.1210/mend.12.1.0044.

Vayssaire BM, Dupont S, Choquart A, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiiflammatory activity in vivo. Mol Endocrinol. 1997;11(9):1245-1255. https://doi.org/10.1210/mend.11.9.9979.

Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004;50(11):3408-3417. https://doi.org/10.1002/art.20583.

Bashkova IB, Madjanov IV. Guidelines for the management of patients with glucocorticoid-induced osteoporosis. RMJ. 2018;12(2):99-102.(in Russian).

Golovach IYu. Glucocorticoid-induced osteoporosis: historical aspects and modern approaches to prevention and treatment. Farmateka. 2015;S4:50-55. (in Russian).

Povoroznjuk VV, Nejko YM, Golovach IYu. Gljukokortykoid-indukovanyj osteoporoz [Glucocorticoid-induced osteo-porosis]. Kyiv: TMK; 2000. 208 p. (in Ukrainian).

Van Staa T, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteo-poros Int. 2002:13(10):777–787. https://doi.org/10.1007/s001980200108.

Fardet L, Petersen I. Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology (Oxford). 2011 Nov;50(11):1982-90. https://doi.org/10.1093/rheumatology/ker017.

Overman RA, Yeh JY, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population per-spective. Arthritis Care Res (Hoboken). 2013 Feb;65(2):294-298. doi: 10.1002/acr.21796. https://doi.org/10.1002/acr.21796.

van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United King-dom. Q Med J. 2000;93(2):105-111. https://doi.org/10.1093/qjmed/93.2.105.

Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018;61(1):7-16. https://doi.org/10.1007/s12020-018-1588-2.

Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis. 2002; 61(1): 32-36. https://doi.org/10.1136/ard.61.1.32.

Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004 Jun;19(6):893-9. https://doi.org/10.1359/JBMR.040134.

Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39(12):1383-1389. https://doi.org/10.1093/rheumatology/39.12.1383.

Amiche MA, Albaum JM, Tadrous M, et al. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression lever-aging control arms of osteoporosis clinical trials. Osteoporos Int. 2016 May;27(5):1709-18. https://doi.org/10.1007/s00198-015-3455-9.

Balasubramanian A, Wade SW, Adler RA, et al. Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int. 2016;27(11):3239-3249. https://doi.org/10.1007/s00198-016-3646-z.

Etminan M, Sadatsafavi M, Ganjizadeh Zavareh S, Takkouche B, FitzGerald JM. Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta-analysis. Drug Saf. 2008;31(5):409-414. https://doi.org/10.2165/00002018-200831050-00005.

Toogood JH, Baskerville JC, Markov AE, et al. Bone mineral density and the risk of fractures in patients receiving long-term inhaled steroid therapy for asthma. J Allergy Clin Immunol. 1995 Aug;96(2):157-66. https://doi.org/10.1016/s0091-6749(95)70003-x.

Van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res. 2001 Mar;16(3):581-8. https://doi.org/10.1359/jbmr.2001.16.3.581.

Wong CA, Walsh LJ, Smith CJ, et al. Inhaled corticosteroid use and bone mineral density in patients with asthma. Lan-cet. 2000 Apr 22;355(9213):1399-403. https://doi.org/10.1016/S0140-6736(00)02138-3.

Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with systemic and topical corticosteroids. J Intern Med. 2005 Apr;257(4):374-84. https://doi.org/10.1111/j.1365-2796.2005.01467.x.

Bijlsma JW, Duursma SA, Bosch R, Raymakers JA, Huber-Bruning O. Acute changes in calcium and bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis. Br J Rheumatol. 1988;27(3):215-219. https://doi.org/10.1093/rheumatology/27.3.215.

Lems WF, Gerrits MI, Jacobs JW, van Vugt RM, van Rijn HJ, Bijlsma JW. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 1996;55(5): 288-293. https://doi.org/10.1136/ard.55.5.288.

van der Veen MJ, Bijlsma JW. Effects of different regimes of corticosteroid treatment on calcium and bone metabolism in rheumatoid arthritis. Clin Rheumatol. 1992;11(3):388-392. https://doi.org/10.1007/bf02207199.

Leib ES, Saag KG, Adachi JD, et al. Official Positions for FRAX(®) clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX(®) of the 10 year risk of fracture from Joint OfficialPositions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). J Clin Densitom. 2011;14(3):212-9. https://doi.org/10.1016/j.jocd.2011.05.014.

De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 2007;56(1):208-14. https://doi.org/10.1002/art.22294.

Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol. 2010;6(2):82-88. https://doi.org/10.1038/nrrheum.2009.259.

Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M. Glucocorticoid-induced osteoporosis: a systematic re-view and cost-utility analysis. Health Technol Assess. 2007;11(7):iii-iv, ix-xi, 1-231. https://doi.org/10.3310/hta11070.

Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif Tissue Int. 2008;82(4):249-257. doi: 10.1007/s00223-008-9124-7. https://doi.org/10.1007/s00223-008-9124-7.

Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22(3):809-16. https://doi.org/10.1007/s00198-010-1524-7.

Cooper MS, Bujalska I, Rabbitt E, et al. Modulation of 11-beta hydroxysteroid dehydrogenase enzymes by proin-flammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation. J Bone Miner Res. 2001 Jun;16(6):1037-44. https://doi.org/10.1359/jbmr.2001.16.6.1037.

Cooper MS, Blumsohn A, Goddard PE, et al. 11 betahydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone. J Clin Endocrinol Metab. 2003 Aug;88(8):3874-7. https://doi.org/10.1210/jc.2003-022025.

Golovach IY. Problems of glucocorticoid resistance: mechanisms of development and importance for clinical practice. Ratsionalnaya farmakoterapiya. 2012;1(22):29-32. (in Ukrainian).

Rizzoli R, Biver E. Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheu-matol. 2015;11(2):98-109. doi: 10.1038/nrrheum.2014.188. https://doi.org/10.1038/nrrheum.2014.188.

Bressot C, Meunier PJ, Chapuy MC, Lejeune E, CEdouardA.JDarby. Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Metab. Bone Dis. Rel. Res. 1979;1(4):303-311. https://doi.org/10.1016/0221-8747(79)90024-9.

Dalle Carbonare L, Arlot ME, Chavassieux PM, Roux JP, Portero NR, Meunier PJ. Comparison of trabecular bone archi-tecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res. 2001 Jan;16(1):97-103. https://doi.org/10.1359/jbmr.2001.16.1.97.

Dempster DW. Bone histomorphometry in glucocorticoidinduced osteoporosis. J Bone Miner Res. 1989 Apr;4(2):137-41. https://doi.org/10.1002/jbmr.5650040202.

Wu Z, Bucher NLR, Farmer SR. Induction of peroxisome proliferator-activated receptor γ during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPh, C/EBPy, and glucocorticoids. Mol Cell Biol. 1996 Aug;16(8):4128-36. https://doi.org/10.1128/mcb.16.8.4128.

Ohnaka K, Tanabe M, Kawate H, Nawata H, Takayanagi R. Glucocorticoid suppresses the canonical Wnt signal in cul-tured human osteoblasts. Biochem Biophys Res Commun. 2005 Apr 1;329(1):177-81. https://doi.org/10.1016/j.bbrc.2005.01.117.

Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. Bone. 2017 Mar;96:29-37. https://doi.org/10.1016/j.bone.2016.10.007.

Pereira RC, Delany AM, Canalis E. Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone. 2002 May;30(5):685-91. https://doi.org/10.1016/s8756-3282(02)00687-7.

Swanson C, Lorentzon M, Conaway HH, Lerner UH. Glucocorticoid regulation of osteoclast differentiation and expres-sion of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones. Endocrinology. 2006 Jul;147(7):3613-22. https://doi.org/10.1210/en.2005-0717.

Mazziotti G, Formenti AM, Adler RA, et al. Glucocorticoidinduced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines. Endocrine. 2016 Dec;54(3):603-611. https://doi.org/10.1007/s12020-016-1146-8.

Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007 Oct;18(10):1319-28. https://doi.org/10.1007/s00198-007-0394-0.

Majumdar SR, Lix LM, Yogendran M, Morin SN, Metge CJ, Leslie WD. Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998-2008). J Clin Endocrinol Metab. 2012 Apr;97(4):1236-42. https://doi.org/10.1210/jc.2011-2645.

Bone and Tooth Society of Great Britain, National Osteoporosis Society, Royal College of Physicians. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London: RCP; 2002.

Geusens PP, de Nijs RN, Lems WF, et al. Prevention of glucocorticoid osteoporosis: a consensusdocument of the Dutch Society for Rheumatology. Ann Rheum Dis. 2004 Mar;63(3):324-5. https://doi.org/10.1136/ard.2003.008060.

Nawata H, Soen S, Takayanagi R, et al. Guidelines on the management and treatment of glucocorticoid-induced osteo-porosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab. 2005;23(2):105-109. https://doi.org/10.1007/s00774-004-0596-x.

Devogelaer JP, Goemaere S, Boonen S, et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int. 2006;17(1):8-19. https://doi.org/10.1007/s00198-005-2032-z.

Pfeilschifter J, Kurth AA. DVO guidelines 2009 for prevention, diagnosis and therapy of osteoporosis in adults. Osteolo-gie.2011;20(1):55-74.

Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the pre-vention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010 Nov;62(11):1515-26. https://doi.org/10.1002/acr.22023.

Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of oste-oporosis in Canada: summary. CMAJ. 2010 Nov 23;182(17):1864-73. https://doi.org/10.1503/cmaj.100771.

Pereira RM, Carvalho JF, Paula AP, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev Bras Reumatol. 2012;52(4):580-593.

Lekamwasam S, Adachi JD, Agnusdei D, et al. An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis. Arch Osteoporos. 2012;7:25-30. https://doi.org/10.1007/s11657-012-0070-7.

Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23(9):2257-2276. https://doi.org/10.1007/s00198-012-1958-1.

Briot K, Cortet B, Roux C, et al. 2014update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine. 2014 Dec;81(6):493-501. https://doi.org/10.1016/j.jbspin.2014.10.001.

National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. Washington DC: Na-tional Osteoporosis Foundation; 2014.

Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2001;44(7):1496-1503. https://doi.org/10.1002/1529-0131(200107)44:7%3C1496::AID-ART271%3E3.0.CO;2-5.

Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treat-ment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheum. 2017;69(8):1521-1537. https://doi.org/10.1002/art.40137.

den Uyl D, Bultink IEM, Lems WF. Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep. 2011;13(3):233-240. https://doi.org/10.1007/s11926-011-0173-y.

Lesnjak OM, Baranova IA, Toropcova NV. Diagnostika, profilaktika i lechenie gljukokortikoidnogo osteoporoza u mu-zhchin i zhenshhin 18 let i starshe: Klinichekie rekomendacii [Diagnosis, prevention and treatment of glucocorticoid os-teoporosis in men and women 18 years of age and older: Clinical recommendations]. Jaroslavl: IPK Litera; 2013. 48 p. (in Russian).

van Staa TP, Geuzens P, Pols HA, de Laet C, Leufkens HG, Cooper C. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM. 2005;98(3):191-198. https://doi.org/10.1093/qjmed/hci029.

Yu SF, Chen JF, Chen YC, et al. Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid: A nationwide osteoporosis survey. Medicine (Balti-more). 2017;96(5):e5959. https://doi.org/10.1097/MD.0000000000005959.

Overman RA, Toliver JC, Yeh JY, Gourlay ML, Deal CL. United States adults meeting 2010 American College of Rheu-matology criteria for treatment and prevention of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hobo-ken) 2014;66(11):1644-1652. https://doi.org/10.1002/acr.22346.

Kirigaya D, Nakayama T, Ishizaki T, Ikeda S, Satoh T. Management and treatment of osteoporosis in patients receiving long-term glucocorticoid treatment: current status of adherence to clinical guidelines and related factors. Intern Med. 2011;50(22):2793-800. https://doi.org/10.2169/internalmedicine.50.5266.

Compston J, Cooper A, Cooper C, National Osteoporosis Guideline Group (NOGG). UK clinical guideline for the preven-tion and treatment of osteoporosis. Arch Osteoporos. 2017 Dec;12(1):43. https://doi.org/10.1007/s11657-017-0324-5.

Golovach ІYu. Management of glucocorticoid-induced osteoporosis in the light of the latest recommendations of the American College of Rheumatologists (ACR'2017). Praktikujuchij lіkar. 2017;3(23):5-14. (in Ukrainian).

Curtis JR, Westfall AO, Allison JJ, et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum. 2005 Aug;52(8):2485-94. https://doi.org/10.1002/art.21194.

Feldstein AC, Elmer PJ, Nichols GA, Herson M. Practice patterns in patients at risk for glucocorticoid-induced osteoporo-sis. Osteoporos Int. 2005 Dec;16(12):2168-74. https://doi.org/10.1007/s00198-005-2016-z.

Majumdar SR, Lix LM, Morin SN, Yogendran M, Metge CJ, Leslie WD. The disconnect between better quality of gluco-corticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study. J Rheumatol. 2013 Oct;40(10):1736-41. https://doi.org/10.3899/jrheum.130041.

Trijau S, de Lamotte G, Pradel V, et al. Osteoporosis prevention among chronic glucocorticoid users: results from a pub-lic health insurance database. RMD Open. 2016;2(2): e000249. https://doi.org/10.1136/rmdopen-2016-000249.

Amiche MA, Lévesque LE, Gomes T, et al. Effectiveness of oral bisphosphonates in reducing fracture risk among oral glucocorticoid users: three matched cohort analyses. J Bone Miner Res. 2018 Mar;33(3):419-429. https://doi.org/10.1002/jbmr.3318.






Copyright (c) 2020 I.Yu. Golovach

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2020

 

   Seo анализ сайта